Last update Jan. 22, 2025

Secnidazole

Compatible

Safe product and/or breastfeeding is the best option.

Secnidazole is a derivative of 5-nitroimidazole with properties similar to those of metronidazole. It is used in the treatment of amebiasis, giardiasis and trichomoniasis. Oral administration, one or two doses in a single day (5 days if hepatic amebiasis).

At the date of the last update we found no published data on its excretion in breast milk.

Its pharmacokinetic data (low molecular weight and low protein binding) make it likely to pass into breast milk in quantities that could be significant.

There is no evidence in the scientific literature that it is carcinogenic or mutagenic and it is very unlikely that there is any risk from taking a single dose (FDA 2017). Used in children from 5 kg of weight (Novag 2011), in children under 6 months (Rodriguez 2011, Goto 2009, Toppare 199) or one year of age. (Aventis 2011)

Until more published data on this drug in relation to breastfeeding are known, safer and shorter half-life alternatives may be preferable, especially during the neonatal period and in case of prematurity. 

Alternatives

  • Clindamycin (Safe product and/or breastfeeding is the best option.)
  • Metronidazole (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Secnidazole in other languages or writings:

Groups

Secnidazole belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Secnidazole in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 185 daltons
Protein Binding < 5 %
VD 0.6 l/Kg
pKa 15.16 -
Tmax 1 - 3 hours
25 - 30 hours

References

  1. FDA. Secnidazole. Drug Summary. 2017 Full text (in our servers)
  2. Rodríguez Grullón JM, Castellanos Nouel M, Romero Suero Y, Rodríguez Caro R. Eficacia del Secnidazol a dosis única. Acta Médica Dominicana 31(1):23-26 2011 Abstract Full text (link to original source) Full text (in our servers)
  3. Novag Secnidazol (Minovag) Ficha técnica 2011 Full text (in our servers)
  4. Aventis Pharma Secnidazol (Secnidal) Ficha técnica 2011 Full text (in our servers)
  5. Goto R, Mascie-Taylor CG, Lunn PG. Impact of anti-Giardia and anthelminthic treatment on infant growth and intestinal permeability in rural Bangladesh: a randomised double-blind controlled study. Trans R Soc Trop Med Hyg. 2009 Abstract
  6. Gillis JC, Wiseman LR. Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs. 1996 Abstract
  7. Toppare MF, Kitapçi F, Senses DA, Yalcinkaya F, Kaya IS, Dilmen U. Ornidazole and secnidazole in the treatment of symptomatic intestinal amoebiasis in childhood. Trop Doct. 1994 Abstract
  8. Sinuhaji AB, Lubis CP, Daulay HR, Hamid ED, Lubis IT, Jufri A, Sutanto AH. A double blind trial between metronidazole and secnidazole in acute amebic dysentery in children (preliminary report). Paediatr Indones. 1986 Abstract

Total visits

107,538

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM